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Abstract 
 
The increase of cancer specificity and efficacy of anti-tumoral agents are prime strategies to 
overcome the deleterious side effects associated with anti-cancer treatments. We described 
earlier a cell-permeable protease-resistant peptide derived from the p120 RasGAP protein, 
called TAT-RasGAP317-326, as being an efficient tumor-specific sensitizer to apoptosis induced 
by genotoxins in vitro and in vivo. Bcl-2 family members regulate the intrinsic apoptotic 
response and as such could be targeted by TAT-RasGAP317-326. Our results indicate that the 
RasGAP-derived peptide increases cisplatin-induced Bax activation. We found no evidence, 
using in particular knock-out cells, of an involvement of other Bcl-2 family proteins in the 
tumor-specific sensitization activity of TAT-RasGAP317-326. The absence of Bax and Bak in 
mouse embryonic fibroblasts (MEFs) rendered them resistant to cisplatin-induced apoptosis 
and consequently to the sensitizing action of the RasGAP-derived peptide. Surprisingly, in the 
HCT116 colon carcinoma cell line, the absence of Bax and Bak did not prevent cisplatin-
induced apoptosis and the ability of TAT-RasGAP317-326 to augment this response. Our study 
also revealed that p53, while required for an efficient genotoxin-induced apoptotic response, 
is dispensable for the ability of the RasGAP-derived peptide to augment the capacity of 
genotoxins to decrease long-term survival of cancer cells. Hence, even though genotoxin-
induced Bax activity can be increased by TAT-RasGAP317-326, the sensitizing activity of the 
RasGAP-derived peptide can operate in the absence of a functional mitochondrial intrinsic 
death pathway. 
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Introduction 
The modulation of tumor cell sensitivity to genotoxic agents is one major issue in anticancer 
research 1. The development of small molecules able to selectively increase the susceptibility 
of cancer cells to genotoxin-induced cell death would ameliorate the efficacy of 
chemotherapy and offer substantial benefits to individuals with cancer. A few compounds 
have been demonstrated to act as tumor sensitizers. These compounds are generally devoid, 
on their own, of any cytostatic or cytolytic effect on cells but they increase the ability of 
known anti-cancer agent to kill tumor cells. ADD70 corresponds to a fragment of the AIF 
(apoptosis-inducing factor) protein that binds the Hsp70 heat shock protein 2. When expressed 
in colon carcinoma and lymphoma, ADD70 sensitizes them to cisplatin 3. However, ADD70 
does not have the ability to enter cells and cannot therefore be used as is as a tumor sensitizer 
in vivo. SmacN7 is a short 7 amino acid long peptide derived from Smac/Diablo, a protein 
released by the mitochondria in response to apoptotic stimuli that inhibits IAPs (inhibitor of 
apoptosis proteins) and hence favors the apoptotic process 4. While apparently not inducing 
apoptosis of cancer cells by itself, a cell-permeable version of SmacN7 potentiates the action 
of genotoxins 5-7. 
Our laboratory has developed an anti-tumor peptide that selectively sensitizes several cancer 
cell lines, but not non-cancer cell lines, to genotoxin-induced apoptosis 8. The anti-tumor 
activity of this peptide is a carried by a ten-amino acid long sequence derived from the SH3 
domain of p120 RasGAP. This sequence corresponds to residues 317-326 of the RasGAP 
protein 8. The RasGAP317-326 peptide was made cell permeable by hooking it to a short 
sequence of the HIV-TAT protein (residues 48 to 57) that allows polypeptides to penetrate 
cells 9, resulting in the so-called called TAT-RasGAP317-326 peptide. This compound by itself, 
does not affect cell viability 8. The RasGAP-derived peptide is also capable of increasing the 
anti-cancer activity of cisplatin and doxorubicin against human tumor xenografts 10 and to 
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augment the killing efficiency of photodynamic therapy in mesothelioma cells 11. Recently, 
TAT-RasGAP317-326 was shown to inhibit migration and invasion in vitro, indicating that it 
has the potential to function as an anti-metastatic compound 12. 
Genotoxins are DNA-damaging substances that exert their anti-tumor activity by causing 
apoptosis in cancer cells mainly through the mitochondrial pathway 13-15. The genotoxin-
induced DNA-damage response is orchestrated by a series of kinases (e.g. the ataxia-
telangiectasia mutated, ATM) that sense the extent of the damage and activate downstream 
effectors 16,17. One of the key DNA damage response effector is p53, a transcription factor that 
regulates the expression of genes involved in cell cycle arrest (e.g. p21) and apoptosis (e.g. 
Puma and Bax) 18. Puma and Bax both belong to the Bcl-2 family member that tightly 
controls, directly or indirectly, the release of pro-apoptotic molecules from the mitochondria 
19. Members of this family share up to four BH (Bcl-2 Homology) domains and are 
conventionally subdivided into three groups on the basis of their pro- or anti-apoptotic 
activity and the BH domains they contain. Anti-apoptotic players (Bcl-2, Bcl-XL, Bcl-w, Mcl-
1 and A1) and pro-apoptotic players (Bax, Bak and Bok) possess four BH domains, whereas 
the pro-apoptotic BH3-only proteins (Bid, Bim, Bad, Bmf; Bik, Noxa, Puma and Hrk) display 
only the BH3 domain 20. When the balance between pro- and anti-apoptotic members of this 
family tips in favor of the former, mitochondrial membrane integrity is lost, cytochrome c is 
released in a Bax/Bak-dependent manner and this leads to caspase activation and apoptosis 21. 
There are currently two main models describing how these proteins determine cell fate. These 
models are not necessarily mutually exclusive 22-24. According to the ‘indirect model’, pro-
apoptotic Bax and Bak are neutralized by anti-apoptotic proteins (e.g. Bcl-2) under normal 
conditions. When cells are subjected to apoptotic insults, BH3-only proteins displace Bax and 
Bak from their guardians allowing them to oligomerize in the outer mitochondria membrane, 
leading to cytochrome c release and cell death 25. Conversely, the ‘direct model’ supports a 
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direct Bax/Bak activating role for a subgroup of the BH3-only members (tBid, Bim and 
Puma) called the ‘activators’. In basal conditions, these are sequestered by the anti-apoptotic 
proteins but in response to apoptotic stimuli they are displaced by the BH3-only ‘sensitizers’ 
members (e.g. Bad and Noxa). The freed ‘activators’ can then promote the oligomerization of 
Bax and Bak 26,27. 
We showed earlier that TAT-RasGAP317-326 does not modulate MAPK signaling pathways 
(p38, ERK and JNK), NF-κB transcriptional activity or Akt protein levels and 
phosphorylation status 28,29. Here we show that the activity of Bax can be modulated by TAT-
RasGAP317-326 in the context of tumor cells sensitization to genotoxin-induced apoptosis. Our 
data indicate however that Bcl-2 family members, including Bax and Bak, are dispensable for 
the capacity of the peptide to increase forms of deaths distinct from the classical 
mitochondrial apoptotic pathway. 
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Materials and methods 
Chemicals 
Cisplatin (Sigma, ref. n°P4394) was dissolved in water at a 1 mg/ml concentration and stored 
at -80°C. TNFα (Pierce, ref. n°RTNFA10) was dissolved in water at a concentration of 10 
μg/ml, aliquoted and stored at -80°C. Cycloheximide (Sigma, ref. n°C7698) was dissolved in 
methanol at 20mg/mL and stored at -20 °C. Paraformaldehyde (PFA) and HCl were from 
Acros (ref. n°30525-89-4 and 7647-01-0, respectively). Hoechst 33342 (Molecular Probe, 
Invitrogen, ref. n°H21492) was prepared as a 10 mg/ml water solution, stored at 4°C and used 
at a final concentration of 10 μg/ml. The pan-caspase inhibitor MX1013 was a kind gift from 
Maxim Pharmaceuticals (San Diego, CA). Tris, sodium dodecyl sulfate (SDS), mannitol, 
sucrose and trichloroacetic acid were from Sigma (ref. n°T1503, L4390, M4125, S0389 and 
T9159 respectively). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was from 
AppliChem (ref. n°A3724). NaCl, EGTA (ethylenebis[oxyethylenenitrilo]tetraacetic acid) and 
bromophenol blue were from Acros (ref. n°7647-14-5, 67-42-5, and 115-39-9, respectively). 
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) was from Fluka and 
AppliChem (ref. n°26680 and A1099.0050 respectively). EDTA (ethylenediaminetetraacetic 
acid), dithiothreitol (DTT), KCl and glycerol were from Fluka (ref. n°03620, 43817, 60130 
and 49780, respectively). G-Sepharose beads were from GE Healthcare (ref. n°17-0618-01). 
Dynabeads Protein G was from Life Technologies (ref. n°10004D). Nitrocellulose membranes 
and gel filtration standard markers were from Biorad (ref. n°162-0115 and 151-1901 
respectively). MgCl2 was from Eurobio (ref. n°018023). EDTA-free Protease Inhibitor 
Cocktail Tablets were from Roche Applied Science (ref. n°1873580). Polyoxyethylene (20) 
sorbitan monolaurate (Tween 20) was from AppliChem (ref. n° 90005-64-5). SM-164 was 
synthetized as described 30. 
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Buffers  
The composition of phosphate buffered saline (PBS) is 116 mM NaCl, 10.4 mM Na2HPO4, 
3.2 mM KH2PO4 (pH 7.4). The composition of the isotonic mitochondrial buffer (MB) is 10 
mM HEPES (pH 7.4), 210 mM mannitol, 70 mM sucrose, 1 mM EDTA supplemented with 
one tablet of EDTA-free inhibitor (Roche) per 50 ml. The KCl buffer is made of 10 mM 
HEPES (pH 7.4), 125 mM KCl, 0.5 mM EGTA, 4 mM MgCl2 and 5mM KHPO4. 1% 
CHAPS lysis buffer is made of 5 mM MgCl2, 137 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% CHAPS, 20 mM Tris-HCl, supplemented with one tablet of EDTA-free Protease Inhibitor 
Cocktail (Roche) per 50 ml. MonoQ-c buffer is made of 70 mM β-glycerophosphate, 0.5% 
Triton X-100, 2 mM MgCl2, 1 mM EGTA, 100 µM Na3VO4, 1 mM dithiothreitol, 20 µg/ml 
aprotinin supplemented with one tablet of complete EDTA-free Protease Inhibitor Cocktail 
per 50 ml. The composition of the elution buffer is 25 mM Hepes-NaOH pH7.5, 200mM 
NaCl, 1% CHAPS (W/V), 2mM DTT. 
 
Peptides 
TAT and TAT-RasGAP317-326 are retro-inverso peptides (i.e. synthesized with D-amino acids 
in the opposite direction compared to the natural sequence).  The TAT moiety corresponds to 
amino acids 48-57 of the HIV TAT protein (RRRQRRKKRG) and the RasGAP317-326 moiety 
corresponds to amino acids 317-326 of the human RasGAP protein (DTRLNTVWMW). 
These two moieties are separated by two glycine linker residues in the TAT-RasGAP317-326 
peptide. The peptides were synthesized at the Institute of Biochemistry, University of 
Lausanne, Switzerland, using FMOC technology, purified by HPLC and tested by mass 
spectrometry. 
 
Cell lines 
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U2OS, HCT116 were cultured in DMEM (Invitrogen, ref. n°61965) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; Invitrogen, ref. n°10270-106) in 5% CO2 at 37°C. 
HeLa cells were cultured in RPMI (Invitrogen, ref. n°61870) supplemented with 10% heat-
inactivated FBS in 5% CO2 at 37°C. Culturing of the cells prior to performing the 
experiments described in this article was performed in six-well plates by seeding 100'000 
cells (Figure 1; Figure 5B), 150'000 (Figure 2, U2OS and HeLa cells), 200'000 (Figure 2, 
HCT116 cells), or 250'000 cells (Figure 5A; Figure 6) in the wells 24 hours before being 
treated as indicated in the figures. HeLa cells were infected with LeGo-iT2 empty and LeGO-
iT2-Bcl-xL lentiviruses. Knock-out (KO) mouse embryonic fibroblast (MEFs) for Bcl-XL, 
Bcl-2, Mcl-1, Bim, Bmf and Bid were transformed by infecting them with a SV40 large T-
encoding lentivirus 31,32. KO MEFs for Bax, Bak, Bax/Bak and Bad were provided by the late 
Dr. Stanley Korsmeyer. Culturing of the KO MEFs prior to performing the experiments 
described in this article was performed during 24h in six-well plates by seeding 150'000 cells 
(Figure 4). For starvation, cells were washed three times with PBS and incubated for 24 hours 
with medium lacking FBS. 
 
TRAIL-induced apoptosis 
Cells were incubated for 24h with recombinant Flag-TRAIL and 2 µg/mL anti-FLAG M2 
antibody diluted in culture medium. 
 
UV illumination  
Cells in culture dishes with the lid removed were UV-C- illuminated using the UV lamp of a 
cell culture hood (Fortuna from Scanlaf 1200) delivering an intensity of 0.25 J/m2 per second. 
The cells were then incubated for the indicated periods of time in 5% CO2 at 37°C. 
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Apoptosis quantitation 
Cells were fixed in 2% PFA and nuclei labeled with Hoechst 33342. Apoptotic cells (i.e. cells 
displaying a pycnotic nucleus) were counted under a Nikon Eclipse TS100 microscope. When 
apoptosis was assessed on a population of transfected cells, only green cells (i.e. cells having 
incorporated the transfected plasmids) were counted.  
 
Statistics 
The statistical analyses were done with Microsoft Excel (XP edition) using the unpaired 
Student’s t-test. Significance is indicated by an asterisk when P < 0.05/n, where P is the 
probability derived from the t test analysis and n is the number of comparisons done 
(Bonferroni correction). For Figures 4, 6, and 8, the statistical test used was one-way ANOVA 
followed by Bonferroni's post-hoc comparisons tests. 
 
Transfection 
Cells were transfected using Lipofectamine 2000 (GibcoBRL, ref. n°18324-012) according to 
the manufacturer's instructions. Briefly, the indicated plasmids, together with 0.5 µg of GFP-
encoding plasmid, were diluted in 250 µl DMEM without FBS. The amount of DNA used in 
the transfection was kept constant to 4 µg by adding the appropriate quantities of the pcDNA3 
empty vector. In parallel, 8 µl of lipofectamine were added to 250 µl of DMEM without FBS 
and kept at room temperature for 5 minutes. Finally, the DNA-containing medium was added 
drop by drop to the lipofectamin-containing medium and the resulting 500 µl mix was added 
to cells. Five hours later, cells were washed once with fresh medium (DMEM supplemented 
with FBS) and cultured for an additional 20 hour period in the presence of the treatments 
indicated in the figures. 
 
 10 
Coimmunoprecipitation and immunoblotting 
7.5x105 U2OS and HeLa cells and 106 HCT116 cells were seeded in 10 cm plates and the 
next day treated as shown in the figures. Sixteen hours later, the cells were lysed in 300 μl of 
1% CHAPS lysis buffer and 700 μg of the lysate proteins were immunoprecipitated overnight 
with 1.5 μg of the 6A7 anti-Bax antibody (Figure 2). Immunoprecipitates were captured on 30 
μl of protein G-Sepharose at 4 °C for 2 hours. Immunocomplexes were then washed three 
times in CHAPS lysis buffer and eluted in 30 μl of 2x sample buffer [25 mM Tris-HCl pH 
7.5, 10% glycerol, 6% SDS, 0.02% of bromophenol blue and 100 mM freshly added DTT]. 
The immunoprecipitates and 50 μg of total cell lysates were separated by SDS-PAGE and 
then transferred onto nitrocellulose membrane. The membranes were blocked with TBS (20 
mM Tris, 130 mM NaCl, pH 7.6) containing 0.1% Tween 20 and 5% non-fat milk (TBS-TM) 
and incubated overnight at 4°C with a 1:1000 dilution of the N-20 anti-Bax antibody (Figure 
2) or 1:1000 dilutions of the antibodies directed at the proteins indicated in the other figures. 
Blots were then washed with TBS containing 0.1% Tween 20 (TBS-T), incubated 1 hour at 
room temperature with the appropriate fluorophore-conjugated secondary antibody (1:5000 
dilution) and subsequently visualized with the Odyssey infrared imaging system (LICOR 
Biosciences, Bad Homburg, Germany). Bak immunoprecipitation was performed as described 
above with the following modifications: 2000 μg of the lysate proteins were 
immunoprecipitated overnight with 1.5 μg of the Ab-2 anti-Bak antibody (Figure 2E). 
Immunoprecipitates were captured with 15 μl of Dynabeads Protein G. 
 
Crosslinking of mitochondrial proteins 
HeLa cells were harvested in PBS and centrifuged 10min at 1000 g. Cells were then 
resuspended in isotonic mitochondrial buffer (MB), broken by five passages through a 25G1 
0.5- by 2.5 mm needle fitted on a 2 ml syringe and centrifuged at 1500 g for 5 min. This 
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procedure was repeated twice and supernatants from each step were pooled and centrifuged 5 
min at 1500 g. Supernatant was collected, centrifuged 5min at 2000 g and further centrifuged 
10 min at 9000 g. Pellet was resuspended in MB (100 µL) and centrifuged 10min at 7000 g 
and the pellet, representing the mitochondrial fraction, was finally resuspended in MB. 
Mitochondria (40 µg) were incubated for 30 min at room temperature with DSS 5 mM. The 
reaction was stop by addition of 1 M Tris-HCl pH 8 quenching buffer. Mitochondria were 
centrifuged, resuspended in Ripa lysis buffer and incubated on ice for 15 min. After 
centrifugation at maximum speed, the supernatant was collected, mixed with loading buffer 
and analyzed by western blot using anti-Bax antibody. 
 
Western blotting 
Cells were lysed in 100 µl of monoQ-c buffer. Visualization of the bands was performed 
using the Odyssey infrared imaging device and software (Licor, Homburg, Germany). Protein 
levels were quantitated using ImageJ software. 
 
Antibodies 
The anti-Puma rabbit polyclonal IgG antibody, the anti-Bid rabbit polyclonal antibody, the 
anti-Bcl-XL rabbit polyclonal IgG antibody, and the anti-caspase-3 rabbit polyclonal IgG 
antibody were from Cell Signaling (ref. n°4976, 2002, 2764 and 9665, respectively). The 6A7 
anti-active Bax mouse monoclonal IgG1, the N-20 anti-total Bax rabbit polyclonal IgG, and 
the G23 anti-total Bak rabbit polyclonal IgG antibodies were from SantaCruz (ref. n°sc-
23959, n°sc-493 and n°sc-832 respectively). The anti-Bcl-2 mouse monoclonal IgG1 antibody 
was from Upstate (ref. n°05-341), the Y37 anti-Mcl-1 rabbit monoclonal IgG antibody was 
from Abcam (ref. n°ab32087), the 3C5 anti-Bim rat monoclonal IgG2a antibody and the 1E1-
1-10 anti-cIAP1 rat monoclonal IgG2a antibody were from Enzo Life Sciences (ref. n°ALX-
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804-527-C100 and n°ALX-803-335-C100, respectively). The 48/hILP/XIAP anti-XIAP 
mouse monoclonal IgG1 antibody was from BD Biosciences (ref. n°610762). The Ab-2 anti-
active Bak mouse monoclonal IgG2b antibody was from Merck (ref. n°AM04). The mouse 
monoclonal anti-FLAG M2 antibody was from Sigma (ref. n° F1804). Secondary antibodies 
were goat anti-mouse IRDye800-conjugated antibody (Rockland, ref. n°610-132-121), goat 
anti-rabbit Alexa Fluor 680-conjugated antibody (Molecular Probes, ref. n°A21109) and 
donkey anti-rabbit HRP-conjugated antibody (Jackson ImmunoResearch, ref. n° 711-035-
152). 
 
Plasmids 
The pcDNA3 expression vector is from Invitrogen. pEGFP-C1 (Clontech) encodes the green 
fluorescent protein. Puma.cmv (Origene) encodes human Puma. hTPP53.dn3 encodes the 
human p53. It was generated by subcloning the 1900 bp EcoRI/BamHI fragment from 
hTP53.lti (gift from Richard Iggo) into pcDNA3 opened with the same two enzymes. TRIP-
PGK-IRESNEO-WHV (#350) is a lentiviral vector bearing the neomycine resistance. 
SV40LargeTantigen.pBABE-puro (#731) encodes the SV40 large T antigen (Addgene; 
plasmid 13970). SV40LargeTantigen.lti-neo (#738) similarly encodes the large T antigen 
but in a lentiviral expression vector. It was constructed by subcloning the BamHI 2187 base 
pairs fragment of SV40LargeTantigen.pBABE-puro into TRIP-PGK-IRESNEO-WHV 
opened with the same enzyme. LeGO-iT2-Bcl-xL (#821) was constructed by subcloning the 
770 bp EcoRI fragment from hBcl-xL.dna (#274) in into LeGO-iT2 (Addgene: plasmid 
27343). The extension .lti indicates that the backbone is a lentiviral vector. The extension 
.cmv indicates that the backbone is the pCMV-AC vector. The extension .dn3 indicates that 
the backbone plasmid is pcDNA3. 
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Results 
 
TAT-RasGAP317-326 sensitizes diverse cancer cells to genotoxin-induced apoptosis but 
not to TNFα-induced apoptosis and variably to starvation- and UV-induced apoptosis 
We demonstrated earlier that TAT-RasGAP317-326 sensitizes various cancer cell lines to 
apoptosis induced by genotoxins such as cisplatin and doxorubicin 8. These compounds 
induce apoptosis via the intrinsic apoptosis pathway 13,14. To gain further insight about the 
manner by which TAT-RasGAP317-326 exerts its tumor sensitization effect, HeLa, U2OS, and 
HCT116 cancer cells were treated with additional pro-apoptotic compounds, including TNFα 
that induces cell death via the extrinsic apoptotic pathway. Figure 1A shows that TAT-
RasGAP317-326 favored cisplatin-induced apoptosis in the three different cancer cell lines, 
confirming earlier results 8,33. TAT-RasGAP317-326 sensitized some, but not all, tumor cell 
lines to UV- or growth factor deprivation-induced apoptosis, despite the fact that these 
treatments can activate the intrinsic apoptotic pathway 34,35. None of the tumor cell lines was 
sensitized by the peptide to TNFα, an extrinsic pathway stimulator 36,37 in presence of 
cycloheximide (CHX), a protein synthesis inhibitor that prevents the expression of anti-
apoptotic proteins that would otherwise counteract the pro-apoptotic abilities of TNFα 38,39. 
These results suggest that TAT-RasGAP317-326 exerts a pro-apoptotic role in conditions where 
the intrinsic cell death pathway is engaged. However since HeLa and HCT116 are type II 
cells 40,41 (see also Figure 1B), i.e. they need the mitochondrial pathway to fully activate 
caspase-3 in response to extrinsic death stimuli 42, it is unclear why TAT-RasGAP317-326 does 
not have any sensitizing effect on these cell lines when incubated with TNFα. One possibility 
is that CHX prevents the expression of protein that is targeted by TAT-RasGAP317-326 to 
mediate its sensitization effect. To test this hypothesis, we used another extrinsic pathway 
stimulator, TNF-related apoptosis-inducing ligand (TRAIL) 43. Unlike TNFα + CHX, the 
apoptotic response induced by TRAIL was increased by TAT-RasGAP317-326 in HeLa cells 
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(Figure 1B). These cells were confirmed to be type II cells by the complete protection against 
TRAIL-induced apoptosis conferred by Bcl-XL over-expression (Figure 1C).  
 
TAT-RasGAP317-326 increases cisplatin-induced Bax activation 
Tumor cells sensitized by TAT-RasGAP317-326 to genotoxin-induced apoptosis show increased 
caspase-3 activation and more pronounced mitochondrial membrane depolarization 33. This 
suggests that the RasGAP-derived peptide acts upstream of cytochrome c release from 
mitochondria. Consequently, Bax, which is required for mitochondrial outer membrane 
permeabilization, cytochrome c release, and caspase activation 21, should be more activated by 
genotoxins in the presence of TAT-RasGAP317-326. To study the status of Bax activation, we 
performed immunoprecipitation experiments with an antibody (Bax 6A7) that only binds the 
active conformation of Bax. Figure 2A shows that while TAT-RasGAP317-326 alone does not 
affect Bax activation, it increases cisplatin-induced Bax stimulation. Consistent with these 
observations, the peptide did not induce Bax oligomerization by itself but amplified cisplatin-
induced Bax oligomerization (Figure 2B). Figure 2A (lower blots) shows that neither cisplatin 
nor TAT-RasGAP317-326, alone or in combination, alter total Bax cellular levels. However, the 
amount of Bax associated with the mitochondria, either as monomers or dimers, is increased 
in cells treated with cisplatin and TAT-RasGAP317-326 compared to cells treated with cisplatin 
alone (Figure 2B). It appears thus that the RasGAP-derived peptide can facilitate cisplatin-
mediated Bax recruitment to the mitochondria. 
There is evidence that caspase activation induces a positive feedback loop to increase Bax 
activation and cytochrome c release from the mitochondria 44. To determine if TAT-
RasGAP317-326 modulates this feedback loop, the experiment shown in Figure 2A was 
repeated in the presence of the MX1013 pan-caspase inhibitor 45,46 that efficiently blocks 
executioner caspase activity (Figure 2C). Figure 2D shows that caspase inhibition does not 
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prevent TAT-RasGAP317-326 from enhancing cisplatin-mediated Bax activation. The role of 
Bak, the other Bcl-2 family member involved in mitochondrial permeabilization was also 
investigated but we did not observe modulation of cisplatin-induced Bak activation by TAT- 
RasGAP317-326 (Figure 2E). As Bak can substitute for Bax in rendering tumor cells more 
sensitive to cisplatin in the presence of the RasGAP-derived peptide (see below), we currently 
cannot provide an explanation for this observation. 
TAT-RasGAP317-326 does not modulate Bcl-2 and IAP family members 
Bax activation is controlled by pro- and anti-apoptotic members of the Bcl-2 family of 
proteins 19,21. Conceivably, TAT-RasGAP317-326 could favor genotoxin-induced apoptosis by 
increasing the levels of pro-apoptotic Bcl-2 family members and/or decreasing the levels of 
the anti-apoptotic members. However, the peptide did neither modulate the expression of pro-
apoptotic Bim, Puma and Bid proteins nor the anti-apoptotic Bcl-XL, Bcl-2 and Mcl-1 
proteins (Figure 3). Another possibility that could explain how TAT-RasGAP317-326 favors 
apoptosis is inhibition of inhibitor of apoptosis (IAP) family proteins. However, the peptide 
did not alter cellular levels of cIAP1, cIAP2 and XIAP (Figure 3). Therefore, modulation of 
the expression of IAPs and Bcl-2 family members is not the mechanism used by TAT-
RasGAP317-326 to favor Bax activation and apoptosis. However, this does not exclude the 
possibility that the peptide affects the activity of these proteins. 
 
Targeted disruption of individual Bcl-2 family members or IAPs does not prevent TAT-
RasGAP317-326-mediated tumor cell sensitization 
Large T antigen-transformed MEFs lacking specific Bcl-2 family member were used to 
investigate the role of this protein family in the capacity of TAT-RasGAP317-326 to sensitize 
tumor cells to genotoxin-induced apoptosis. MEFs are not cancer cells and hence are not 
susceptible to TAT-RasGAP317-326-mediated genotoxin sensitization. However, transforming 
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MEFs with the SV40 large T antigen renders them sensitive to the peptide 31. Figure 4A 
shows that transformed MEFs lacking the pro-apoptotic BH3-only Bid, Bim, Bmf, or Bad 
proteins or the anti-apoptotic Bcl-XL, Bcl-2, or Mcl-1 proteins were efficiently sensitized by 
TAT-RasGAP317-326 to cisplatin-induced apoptosis. Furthermore, the pro-apoptotic family 
members Bax and Bak, crucial for outer mitochondrial membrane permeabilization are not 
individually required to mediate TAT-RasGAP317-326 sensitization. As expected 47, 
transformed MEFs lacking both Bax and Bak were totally resistant to cisplatin-induced death. 
We next examined the implication of cIAP1/2 and XIAP in TAT-RasGAP317-326 sensitization 
to cisplatin-induced apoptosis. We used the SM-164 Smac mimetic to induce cIAP1/2 
degradation and XIAP inhibition 48. In presence of the Smac mimetic, the sensitization to 
cisplatin induced by the peptide was not altered, despite strong reduction in cIAP1 and cIAP2 
levels, indicating that cIAP1/2 and XIAP are not involved in TAT-RasGAP317-326-mediated 
sensitization of cisplatin-induced apoptosis. 
 
TAT-RasGAP317-326 does not sensitize cells to Puma over-expression 
We previously hypothesized that an intact p53/Puma axis was required for efficient 
genotoxin-induced apoptosis and for TAT-RasGAP317-326 to favor genotoxin-induced 
apoptosis in cancer cells 33. We reasoned that if Puma is necessary and sufficient for the 
sensitizing activity of the RasGAP-derived peptide, ectopic expression of Puma should render 
tumor cells sensitive to TAT-RasGAP317-326 in the absence of cisplatin. Figure 5A shows that 
transfecting U2OS cells with amounts of Puma-encoding plasmids in the 0.5 to 3.5 µg range 
(open circles) led to similar levels of Puma expression than obtained by treating the cells with 
concentrations of cisplatin in the 2.5 to 30 µM range (closed squares). However, TAT-
RasGAP317-326 only sensitized cells incubated with cisplatin and not those transfected with the 
Puma-encoding plasmids (Figure 5B). 
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Puma is a p53 transcription target that may, once synthesized, need p53 to exert its full pro-
apoptotic actions 49. Figure 6 shows that ectopic expression of p53 in U2OS cells induced 
apoptosis. However this was neither modulated by Puma nor by TAT-RasGAP317-326. Taken 
together these data suggest that TAT-RasGAP317-326 does not directly amplify the DNA-
damage-induced p53/Puma arm. Hence, even though cisplatin requires p53 and Puma to 
induce apoptosis 33, this genotoxin may modulate other pro-apoptotic signals that are targeted 
by TAT-RasGAP317-326 to induce cell death in cancer cells. 
 
TAT-RasGAP317-326 affects long term survival of cancer cells independently of p53 
The above observation that the RasGAP-derived peptide does not amplify the p53/Puma axis 
led us to reconsider the implication of p53 in the TAT-RasGAP317-326-mediated sensitization 
of cancer cells. Cells lacking an intact p53/Puma axis show a drastically reduced apoptotic 
rate when exposed to genotoxin treatment 33, but they may remain sensitive to the drugs on 
longer term exposure. Indeed, Figure 7 shows that the survival of either p53-positive or p53-
negative HCT116 cells, tested by colony formation assay, was reduced by cisplatin treatment 
to similar extent. Importantly, TAT-RasGAP317-326 significantly augmented cisplatin-mediated 
cell survival impairment in both cases (Figure 7). It was suggested, based on earlier 
observation that the HCT116 tumor cell line lacking either p53 or Puma did not undergo more 
cisplatin-induced apoptosis in the presence of TAT-RasGAP317-326 33, that TAT-RasGAP317-
326 required a functional p53-Puma axis to exert its sensitizing function. The data presented in 
Figure 7 demonstrate that this initial assumption is not correct. Presumably, the absence of 
p53 or Puma by dramatically increasing the resistance of HCT116 cells to cisplatin-induced 
apoptosis 33 masks the sensitizing effect of the peptide in short-term experiments. Another 
difference to take into account is the method used to evaluate the sensitization to cisplatin. In 
previous report, sensitization was evaluated using apoptosis-specific assays (i.e. scoring cells 
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with pycnotic nuclei). Here, HCT116 p53 KO cells were shown to be sensitized to cisplatin 
using colony formation assays. Apoptosis can affect the ability of cells to form colonies but 
other forms of death (e.g. mitotic catastrophe, necrosis) can too. Hence the results shown in 
Figure 7 indicate that TAT-RasGAP317-326 might sensitize tumors to several types of cell 
death. 
 
TAT-RasGAP317-326 sensitizes HCT116 cells irrespectively of their Bax and Bak status 
Recently, HCT116 cell lines lacking Bax and/or Bak were generated 50. We aimed to 
determine if Bax and Bak were required for cisplatin-induced death and TAT-RasGAP317-326-
mediated sensitization in the HCT116 background as they were in the MEF background (see 
Figure 4). Bax and Bak status in HCT116 wild-type, single KOs and double KO was first 
confirmed by Western blotting (Figure 8A). In contrast to MEFs, the absence of Bax and Bak 
in HCT116 cells reduced, but did not abrogate the ability of cisplatin to induce apoptosis 
(Figure 8B) and, importantly, did not prevent TAT-RasGAP317-326 from sensitizing these cells 
to cisplatin-induced apoptosis. Using colony-formation assays, it was found that cisplatin 
reduced more or less to similar extents the survival of HCT116 cells expressing or not Bax 
and Bak (Figure 8C). The absence of Bax and Bak did not alter the capacity of TAT-
RasGAP317-326 to favor cisplatin-mediated survival decrease. These results indicate that 
apoptosis and cell death induced by genotoxins such as cisplatin can occur in the absence of a 
functional mitochondrial apoptotic pathway (i.e. in the absence of Bax and Bak in HCT116 
cells) and that these modes of death can be augmented by TAT-RasGAP317-326. 
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Discussion 
This study provides advances in the understanding on the mode of action of TAT-RasGAP317-
326. It shows that this peptide enhances cisplatin-induced Bax activation. The RasGAP-derived 
peptide can therefore positively modulate the intrinsic apoptotic pathway activated by 
genotoxins. But the ability of TAT-RasGAP317-326 to favor genotoxin-induced tumor cell 
death is not limited to the intrinsic apoptotic pathway because cisplatin-induced apoptosis and 
TAT-RasGAP317-326-mediated sensitization can occur in cells lacking Bax and Bak and 
because tumor cells lacking p53 can be sensitized by the RasGAP-derived peptide to die by 
an apparently non-apoptotic form of cell death. Hence, TAT-RasGAP317-326-mediated tumor 
cell sensitization to genotoxins can occur independently of Bax, Bak, and p53 through a death 
pathway that remains to be clarified. 
 
Increased Bax stimulation in the context of TAT-RasGAP317-326-mediated sensitization 
Bax and Bak are Bcl-2 family members the activation and oligomerization of which induce 
permeabilization of the mitochondrial outer membrane, resulting in the release of cytochrome 
c 21. This study shows that TAT-RasGAP317-326 increases genotoxin-induced Bax activation. 
However, how this augmentation is accomplished remains unclear. First, the ability of TAT-
RasGAP317-326 to increase genotoxin-induced Bax activation did not require caspase 
activation (Figure 2). Therefore, the peptide does not amplify a positive feedback loop on Bax 
activation induced by the activation of caspases following cytochrome c release 44. Second, 
Bax activation does not result from a peptide-induced balance shift between the expression 
levels of pro- and anti-apoptotic Bcl-2 family members. Indeed, the protein levels of Bcl-2, 
Bcl-XL, Mcl-1, Bim, Puma, and Bid were not modulated by TAT-RasGAP317-326 (Figure 3). 
Moreover, the expression of IAPs was not modified by RasGAP-derived peptide. However, 
this does not exclude the possibility that the peptide affects the activity of these proteins. In 
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addition, all the Bcl-2 family proteins we have tested (Bcl-2, Bcl-XL, Mcl-1, Bim, Bid, Bmf 
and Bad) were shown to be individually dispensable for the sensitizing activity of the peptide. 
This suggests that these proteins are not direct or indirect targets of TAT-RasGAP317-326. 
However, the possibility that the RasGAP-derived peptide targets several Bcl-2 family 
members, which compensate each other when one is absent to mediate the sensitizing action 
of the peptide, cannot be excluded at the present time. Furthermore, HCT116 Bax KO cells 
were found to be sensitized to genotoxin-induced death. This indicates that TAT-RasGAP317-
326 sensitization is not strictly restricted to increased Bax activation. 
 
TAT-RasGAP317-326-mediated sensitization independently of Bax and Bak (and p53) 
In contrast to MEFs, HCT116 cells lacking Bax and Bak can still undergo genotoxin-induced 
apoptosis and this cell death response can be increased by TAT-RasGAP317-326. Moreover, 
HCT116 cells lacking p53, despite being greatly compromised in their ability to apoptose in 
response to genotoxins, as evidenced by their resistance to pycnosis, are nevertheless more 
efficiently killed in long-term survival experiments (colony-formation assays) by genotoxins 
when incubated with the RasGAP-derived peptide. Thus, TAT-RasGAP317-326 has the 
capacity to favor non-mitochondrial forms of cell death. 
Recent findings in non-small-cell lung cancer showed that Bax and Bak are dispensable for 
cisplatin-induced apoptosis 51. In this study, using cisplatin-sensitive and cisplatin-resistant 
cell lines lacking Bax and Bak, it was shown that cisplatin-induced apoptosis may rely on 
caspase-8 activation in an acid sphingomyelinase and FADD-dependent manner. Incidentally, 
it is also noticed that Bax/Bak DKO MEFs were found to be totally resistant to cisplatin-
induced apoptosis in line of the data presented in Figure 4. One could hypothesize that 
apoptosis in Bax/Bak DKO HCT116 cells is mediated through caspase-8 activation and that 
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TAT-RasGAP317-326 increases this response. The implication of caspase-8 in TAT-
RasGAP317-326 cancer cell sensitization remains to be defined however. 
The present report also clarifies the role played by p53 (and Puma) in TAT-RasGAP317-326-
mediated sensitization of tumor cells to genotoxin-induced apoptosis. Interpretations of earlier 
work were that TAT-RasGAP317-326 required a functional p53-Puma axis to favor apoptosis of 
cisplatin-stimulated tumor cells 33. We therefore hypothesized that reproducing expression of 
p53 and Puma in cancer cells, which occurs when cells are treated with cisplatin, would 
render them sensitive to TAT-RasGAP317-326. However, this proved not to be the case (Figure 
5 and 7). Moreover, tumor cells lacking p53, even though highly resistant to cisplatin-induced 
apoptosis in short-term experiments 33, were nevertheless less able to survive long-term 
cisplatin treatment when co-treated with TAT-RasGAP317-326 (Figure 7). This indicates that 
the RasGAP-derived peptide does not require p53 to exert its tumor sensitization activity. 
Hence, p53 and Puma are not targets of TAT-RasGAP317-326. The apparent requirement of p53 
and Puma for the genotoxin-sensitizing function of the peptide in short-term apoptosis assays 
most likely results from the fact that genotoxins inefficiently induce apoptosis of tumor cells 
lacking a functional p53-Puma axis 52. In other words, the absence of TAT-RasGAP317-326-
mediated sensitization observed in p53- or Puma-negative cells merely reflects the fact these 
cells cannot properly undergo genotoxin-induced apoptosis. Measuring cell death in short-
term assays (e.g. within the first 24 hours of treatment) might lead to an underestimation of 
the killing potential of genotoxins, as long-term cell survival is not taken into account. This 
may particularly be the case in cells bearing mutations in apoptosis-controlling proteins. 
Tumor cells lacking p53 can bypass the primary apoptotic decision, which takes place shortly 
after the administration of an apoptotic stimulus, and undergo several cell divisions before 
dying. This can occur either by p53-independent apoptosis or as a result of mitotic catastrophe 
or necrotic cell death 53. The observation that TAT-RasGAP317-326, in combination with 
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cisplatin, reduces the viability of p53-negative tumor cells demonstrates that this peptide can 
also positively reinforces p53-independent cell death mechanism(s) that occur in a more 
delayed manner compared to short-term apoptosis. 
Earlier reports indicate that cisplatin 51 and TRAIL (reviewed in 54) induce caspase-8 
activation. Since the present work shows that TAT-RasGAP317-326 sensitizes tumor cells to 
cisplatin and TRAIL-induced apoptosis, it raises the possibility that the peptide acts at the 
level of caspase-8 or of a caspase 8-containing complex. The activation of caspase-8 is 
modulated by several proteins, for instance positively by Fas-associated death domain protein 
(FADD) and negatively by FADD-like interleukin-1β–converting enzyme (FLICE)-inhibitory 
(cFLIP) 55. Hypothetically, TAT-RasGAP317-326 could favor FADD activity to activate 
caspase-8 or the peptide could neutralize the cFLIP inhibitory effect. Further work is now 
needed to dissect the role played by caspase-8 and its binding partners in the tumor sensitizing 
activities of TAT-RasGAP317-326. 
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Figure legends 
 
Figure 1. Ability of TAT-RasGAP317-326 to sensitize tumor cells to various cell death 
stimuli 
A. U2OS, HeLa and HCT116 were subjected to UV-C illumination or treated during 24 hours 
with various apoptotic stimuli as indicated in the figure. Cells were then fixed and apoptosis 
was counted by scoring pycnotic nuclei. C: 30 μM cisplatin; P: 20 μM TAT-RasGAP317-326; 
TAT: 20 μM; UV-C: 15 J/m2 (U2OS), 25 J/m2 (HCT116 and HeLa); S: starvation; CHX: 10 
μg/ml cycloheximide; TNFα: 1 ng/ml (U2OS and HeLa), 0.5 ng/ml (HCT116). The results 
correspond to the mean +/- 95% CI of independent experiments. The asterisks indicate a 
statistically significant difference between cells treated or not with TAT-RasGAP317-326 in the 
presence of the apoptogenic stimuli. B. HeLa cells overexpressing Bcl-XL or not were treated 
during 24 hours with 20 µM TAT-RasGAP317-326 (P), 200 ng/mL TRAIL (TRAIL). Cells 
were then fixed and apoptosis was counted by scoring pycnotic nuclei. Results correspond to 
the mean +/- 95% CI of 3 independent experiments. The asterisk denotes a statistical 
significant difference. C. HeLa cells were infected with empty virus or virus encoding Bcl-
XL. Bcl-XL expression levels were assessed by Western blotting. 
 
Figure 2. TAT-RasGAP317-326 favors, in a caspase-independent manner, the ability of 
cisplatin to activate Bax 
A. U2OS, HeLa and HCT116 were treated for 16 hours with 20 μM TAT-RasGAP317-326 
and/or with 30 μM of cisplatin as indicated in the figure. The cells were then lysed and Bax 
was immunoprecipitated with an antibody (6A7) that specifically recognizes the active 
conformation of Bax. Western blots were revealed with the N-20 antibody recognizing all 
forms of Bax. IP, immunoprecipitate; TL, total lysate; *, immunoglobulin light chains. B. 
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HeLa cells were treated during 16 hours with 20 μM TAT-RasGAP317-326 and 30 μM cisplatin 
alone or in combination. Mitochondria were isolated and cross-linked with DSS. 
Mitochondrial proteins were extracted and Bax was analyzed by Western blotting. C. 
HCT116 were either left untreated or treated with the indicated concentrations of cisplatin for 
20 hours, in the presence or in the absence of the MX1013 pan-caspase inhibitor. The cells 
were then lysed and the cleavage of caspase-3 was assessed by Western blotting. D. U2OS 
cells were processed as in panel A but in the presence or in the absence of 10 μM MX1013. E. 
HeLa cells were treated for 16 hours with 20 μM TAT-RasGAP317-326 and/or with 30 μM of 
cisplatin as indicated in the figure. The cells were then lysed and Bak was 
immunoprecipitated with an antibody (Ab-2) that specifically recognizes the active 
conformation of Bak. Western blots were revealed with the G23 antibody recognizing all 
forms of Bak. IP, immunoprecipitate; TL, total lysate; *, immunoglobulin light chain; #, non-
specific band.  
 
Figure 3. TAT-RasGAP317-326 does not modulate Bcl-2 family protein levels 
U2OS, HCT116 and HeLa were treated as shown in the figure for 22 hours (TAT-RasGAP317-
326, 20 μM; cisplatin, 30 μM). Cells were then lysed and total protein extracts were 
immunoblotted with antibodies specific for the indicated proteins (*: non-specific band). 
Note: cIAP2 was not detected in HCT116 cells. 
 
Figure 4. Role of individual Bcl-2 family proteins in TAT-RasGAP317-326-mediated 
sensitization to cisplatin-induced apoptosis 
A. SV40-transformed MEFs lacking the indicated Bcl-2 family proteins were treated as 
indicated in the figure for 22 hours. Cells were then fixed and apoptosis was counted by 
scoring pycnotic nuclei. The results correspond to the mean +/- 95%CI of at least three 
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independent experiments. The asterisks indicate a statistically significant difference (as 
assessed by unpaired t-test between cells treated or not with TAT-RasGAP317-326 in the 
presence cisplatin). B. HeLa cells were treated for 16 hours with 20 μM TAT-RasGAP317-326 
(P) and/or with 30 μM of cisplatin (C) in the presence or in the absence of 100 nM Smac 
mimetic (SM) as indicated in the figure. Cells were then fixed and apoptosis was determined 
by scoring pycnotic nuclei. The results correspond to the mean +/- 95 % CI of three 
independent experiments. C. Cells were lysed and cIAP1 and cIAP2 expression controlled by 
Western blotting. 
 
Figure 5. Puma expression per se does not render tumor cells sensitive to TAT-
RasGAP317-326 
A. U2OS were treated with increasing concentrations of cisplatin or transfected with the 
indicated amounts of a Puma-encoding plasmid. Puma protein levels were then determined by 
quantitative Western blotting. B. U2OS cells were treated as in panel A and then incubated or 
not with TAT-RasGAP317-326 (20 μM) for 22 hours. Apoptosis was then determined. Results 
correspond to the mean +/- 95% CI of 3 independent experiments. # indicates a statistically 
significant difference between cells incubated or not with TAT-RasGAP317-326 at given doses 
of cisplatin. $ denotes significant differences to the “0 μM cisplatin” condition. 
 
Figure 6. Ectopic expression of p53 and Puma does not render cancer cells sensitive to 
TAT-RasGAP317-326 
U2OS were transfected with the indicated plasmids and treated or not with 20 μM of TAT-
RasGAP317-326 for 22 hours. Apoptosis was then determined. Results correspond to the mean 
+/- 95%CI of 4 independent experiments. NS, no statistically significant difference. 
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Figure 7. TAT-RasGAP317-326 sensitizes cancer cells to cisplatin-induced cell death 
irrespectively of their p53 status 
Wild-type HCT116 and p53-/- HCT116 were treated with 1 μM cisplatin in the presence or in 
the absence of 20 μM TAT-RasGAP317-326 (P) or 20 μM TAT for 3 days. Culture medium was 
then replaced with fresh medium and following an additional 10-day period the number of 
colonies was recorded. N/T: untreated.  The results correspond to the mean +/- 95% CI of at 
least three independent experiments. The asterisks indicate a statistically significant difference 
between cisplatin-treated cells incubated or not with TAT-RasGAP317-326. 
 
Figure 8. TAT-RasGAP317-326 sensitizes HCT116 cancer cells to cisplatin-induced cell 
death irrespectively of their Bax and Bak status.  
A. Bax and Bak expression was assessed by Western blotting in wild-type (WT) HCT116, 
HCT116 Bak KO, HCT116 Bax KO and HCT116 Bax/Bak DKO cells (*: non-specific band). 
B. WT HCT116 and HCT116 Bax Bak DKO cells were treated during 24 hours with 20 μM 
TAT-RasGAP317-326 (P), 30 μM cisplatin (C). Cells were then fixed and apoptosis was 
assessed by scoring pycnotic nuclei. Results correspond to the mean +/- 95% CI of 3 
independent experiments. The asterisk denotes a statistical significant difference. C. The 
indicated HCT116 cell lines were treated with 2 μM cisplatin in the presence or in the absence 
of 20 μM TAT-RasGAP317-326 (P) or 20 μM TAT for 3 days. Culture medium was then 
replaced with fresh medium and following an additional 10-day period the number of colonies 
was recorded. N/T: untreated. The results correspond to the mean +/- 95% CI of four 
independent experiments. The asterisks indicate a statistically significant difference between 
cisplatin-treated cells incubated or not with TAT-RasGAP317-326. 








